Recent advances in bacteriophage therapy: How delivery routes, formulation, concentration and timing influence the success of phage therapy

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 10, 2011, Pages 1253-1264

  Ryan, Elizabeth M ^a   Gorman, Sean P ^a   Donnelly, Ryan F ^a   Gilmore, Brendan F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

delivery routes; formulation; phage therapy

Indexed keywords

MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; PLACEBO;

ABSENCE OF SIDE EFFECTS; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIOPHAGE; BIOFILM; CHRONIC OTITIS MEDIA; COLONY FORMING UNIT; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SCREENING; DRUG USE; ESCHERICHIA COLI INFECTION; GASTROINTESTINAL INFECTION; HUMAN; INFECTION PREVENTION; KLEBSIELLA PNEUMONIAE INFECTION; LUNG INFECTION; NONHUMAN; REVIEW; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; TOOTH INFECTION; TREATMENT OUTCOME; VIBRIO VULNIFICUS INFECTION; VIROTHERAPY;

ANIMALS; BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOFILMS; BIOLOGICAL THERAPY; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; EQUIPMENT AND SUPPLIES; HUMANS;

EID: 80052590067     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01324.x     Document Type: Review

References (57)

1. d'Hérelle F,. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D'Herelle, presented by Mr. Roux. Res Microbiol 2007; 158: 553-554.
2. d'Hérelle F, Ackermann H-W,. On an invisible microbe antagonistic to dysentery bacilli. Note by M. F. d'Herelle, presented by M. Roux. Comptes Rendus Academie des Sciences 1917; 165: 373-375.
3. Kutter E, Sulakvelidze A,. Bacteriophages: Biology and Applications. New York: CRC Press, 2005: 1-46.
4. Mathews CK, et al,., ed. Bacteriophage T4. Washington, DC: American Society for Microbiology, 1983.
5. Sulakvelidze A, et al,. Bacteriophage therapy. Antimicro Agents Chemo 2001; 45: 649-659. (Pubitemid 32182003)
6. Chopra I, et al,. The search for antimicrobial agents effective against bacteria resistant to multiple antiobiotics. Antimicrob Agents Chemother 1997; 41: 497-503. (Pubitemid 27098393)
7. Infectious Disease Society of America. IDSA Report: Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, a Public Health Crisis Brews. [Online] July 2004;. (Accessed 11 November 2011).
8. Cars O, et al,. Meeting the challenge of antibiotic resistance. BMJ 2008; 337: 726-728.
9. Morel C, Mossialos E,. Stoking the antibiotic pipeline. BMJ 2010; 340: 1115-1118.
10. European Medicines Agency. European Centre for Disease 3 Prevention and Control. Joint technical report: the bacterial challenge-time to react. [Online] September 2009. (Accessed 11 November 2010).
11. Skurnik M, et al,. Phage therapy: fact and fiction. Int J Med Microbiol 2006; 296: 5-14.
12. Clark JR, March JB,. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotech 2006; 24: 212-218.
13. Ackermann HW,. Frequency of morphological phage descriptions in the year 2000. Arch Virol 2001; 146: 843-857.
14. Hanlon GW,. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 2007; 30: 118-128. (Pubitemid 46977193)
15. Summers WC,. Bacteriophage therapy. Annu Rev Microbiol 2001; 55: 437-451. (Pubitemid 32978113)
16. Merril CR, et al,. The prospect for bacteriophage therapy in western medicine. Nat Rev Drug Discov 2003; 2: 489-497. (Pubitemid 37361729)
17. Abedon ST, Loc-Carrillo C,. Pros and cons of phage therapy. Bacteriophage 2011; 1: 111-114.
18. Hyman P, Abedon ST,. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 2010; 70: 217-248.
19. Slopek S, et al,. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp 1987; 35: 569-583.
20. Abedon S, et al,. The 'nuts and bolts' of phage therapy. Curr Pharm Biotechnol 2010; 1: 1-86.
21. Barrow P, et al,. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol 1998; 5: 294-298. (Pubitemid 28246447)
22. Biswas B, et al,. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 2002; 70: 204-210. (Pubitemid 34028619)
23. Abedon ST,. Bacteriophages and Biofilms: Ecology, Phage Therapy, Plaques. New York: Nova publishers, 2011.
24. Cerveny K, et al,. Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun 2002; 70: 6251-6262. (Pubitemid 35192717)
25. Matsuzaki S, et al,. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage fMR11. J Infect Dis 2003; 187: 613-624. (Pubitemid 36250025)
26. Wills QF, et al,. Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 2005; 49: 1220-1221. (Pubitemid 40327754)
27. McVay C, et al,. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrobial Agents Chemother (Bethesda) 2007; 51: 1934-1938. (Pubitemid 46903076)
28. Capparelli R, et al,. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 2007; 51: 2765-2773. (Pubitemid 47206211)
29. Stanford K, et al,. Oral delivery systems for encapsulated bacteriophages targeted at Escherichia coli O157:H7 in feedlot cattle. J Food Prot 2010; 73: 1304-1312.
30. Brussow H,. Phage therapy: the Escherichia coli experience. Microbiology 2005; 151: 2133-2140. (Pubitemid 40984287)
31. Chibani-Chennoufi S, et al,. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother 2004; 48: 2558-2569. (Pubitemid 38823425)
32. Oliveira A, et al,. The influence of the mode of administration in the dissemination of three coliphages in chickens. J Poult Sci 2009; 88: 728-733.
33. Gõrski A, et al,. Bacteriophage translocation. FEMS Immunol Med Microbiol 2006; 46: 313-319.
34. Tanji Y, et al,. Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J Biosci Bioeng 2005; 100: 280-287. (Pubitemid 41755292)
35. Wagenaar JA, et al,. Phage therapy reduces Campylobacter jejuni colonization in broilers. Vet Microbiol 2005; 109: 275-283. (Pubitemid 41073509)
36. Watanabe R, et al,. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 2007; 51: 446-452. (Pubitemid 46185259)
37. Filho RL, et al,. Ability of bacteriophages isolated from different sources to reduce Salmonella enterica serovar enteritidis in vitro and in vivo. Poult Sci 2007; 86: 1904-1909. (Pubitemid 47580895)
38. Markoishvili N, et al,. Phagebioderm-new prospects for treatment of wounds and trophic ulcers. Exp Clin Med 1999; 2: 83-84.
39. Goode D, et al,. Reduction of experimental Salmonella and Campylobacter contamination of chicken skin by application of lytic bacteriophages. Appl Environ Microbiol 2003; 69: 5032-5036. (Pubitemid 36992978)
40. Kumari S, et al,. Topical treatment of Klebsiella pneumoniae B5055 induced burn wound infection in mice using natural products. J Infect Dev Ctries 2010; 4: 367-377.
41. Wright A, et al,. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 34: 349-357.
42. Hawkins C, et al,. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet Microbiol 2010; 146: 309-313.
43. Paisano AF, et al,. In vitro antimicrobial effect of bacteriophages on human dentin infected with Enterococcus faecalis ATCC 29212. Oral Microbiol Immunol 2004; 19: 327-330. (Pubitemid 39232105)
44. Golshahi L, et al,. Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv 2008; 21: 351-360.
45. Golshahi KH, et al,. In vitro delivery of bacteriophages KS4-M and ?KZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J Appl Microbiol 2010; 110: 106-117.
46. Huff WE, et al,. Prevention of Escherichia coli infection in broiler chickens with a bacteriophage aerosol spray. Poult Sci 2002; 81: 1486-1491. (Pubitemid 39615788)
47. Carmody LA, et al,. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis 2010; 201: 264-271.
48. Debarbieux L, et al,. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 2010; 201: 1096-1104.
49. Gilmore BF, Gorman SP,. Antimicrobial devices. In:, Fraise AP, et al., ed. Russell, Hugo & Ayliffe's Principles and Practice of Disinfection, Preservation & Sterilization, 5th edn. Oxford: Wiley-Blackwell, 2011: 1-10. Chapter 21.2 (Ahead of print).
50. Donlan RM, Curtin JJ,. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 2006; 50: 1268-1275.
51. Fu W, et al,. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 2010; 54: 397-404.
52. Carson L, et al,. The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol Med Microbiol 2010; 59: 447-455.
53. Payne RH, et al,. Phage therapy: the peculiar kinetics of self-replicating organisms. Clin Pharmacokinet 2000; 68: 225-230.
54. Payne RH, Jansen VA,. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet 2003; 42: 315-325. (Pubitemid 36433874)
55. Gill JJ, et al,. Efficacy and pharmacokinetics of bacteriophage therapy in treatment of sublinical Staphylococcus aureus in mastitis in lactating dairy cattle. Antimicrob Agents Chemother 2006; 50: 2912-2918. (Pubitemid 44396392)
56. Harper DR, et al,. Bacteriophage applications: where are we now? Appl Microbiol 2010; 51: 363-369.
57. Housby JN, et al,. Phage therapy. Drug Discov Today 2009; 14: 536-540.